We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

36 hedge funds and large institutions have $60.6M invested in DiaMedica Therapeutics in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

114% more capital invested

Capital invested by funds: $28.4M → $60.6M (+$32.2M)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

9% more funds holding

Funds holding: 33 → 36 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.86% less ownership

Funds ownership: 35.8% → 31.93% (-3.9%)

Holders
36
Holders Change
+3
Holders Change %
+9.09%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
11
Reduced
5
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.4M
2
EI
EAM Investors
California
+$602K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$446K
4
CA
Corriente Advisors
Texas
+$421K
5
SSA
Schonfeld Strategic Advisors
New York
+$362K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$3.21M
2
MS
Maven Securities
Jersey
-$1.47M
3
CH
CVI Holdings
Delaware
-$1.17M
4
SCM
Stonepine Capital Management
Oregon
-$1.07M
5
DCM
DAFNA Capital Management
California
-$664K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$9.63M -$1.07M -196,470 -17%
CA
2
Corriente Advisors
Texas
$8.18M +$421K +76,900 +11%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$8.11M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$7.91M +$2.4M +438,054 +128%
MHP
5
Manatuck Hill Partners
Connecticut
$5.79M – – –
GPCM
6
Granite Point Capital Management
Massachusetts
$5.54M -$547K -100,000 -15%
IC
7
Ikarian Capital
Texas
$4.21M – – –
JAMONY
8
Jacob Asset Management of New York
California
$1.42M +$766K +140,000 New
Northern Trust
9
Northern Trust
Illinois
$1.23M +$23.1K +4,222 +4%
Renaissance Technologies
10
Renaissance Technologies
New York
$1.15M +$95.2K +17,400 +18%
EI
11
EAM Investors
California
$1.11M +$602K +109,985 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.05M +$225K +41,037 +65%
Bank of Montreal
13
Bank of Montreal
Ontario, Canada
$764K +$446K +81,572 +26,314%
SSA
14
Schonfeld Strategic Advisors
New York
$671K +$362K +66,250 New
Marshall Wace
15
Marshall Wace
United Kingdom
$607K +$328K +59,871 New
BlackRock
16
BlackRock
New York
$566K +$65.7K +12,008 +27%
BFM
17
Boothbay Fund Management
New York
$472K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$435K +$161K +29,433 +218%
Millennium Management
19
Millennium Management
New York
$414K +$224K +40,861 New
CLG
20
Cooperman Leon G
$304K +$164K +30,000 New
Morgan Stanley
21
Morgan Stanley
New York
$210K +$63.2K +11,560 +127%
Qube Research & Technologies (QRT)
22
Qube Research & Technologies (QRT)
United Kingdom
$190K -$68.1K -12,449 -40%
VF
23
Virtu Financial
New York
$159K +$86K +15,712 New
ECM
24
ExodusPoint Capital Management
New York
$133K +$72K +13,160 New
Jane Street
25
Jane Street
New York
$127K +$68.6K +12,537 New
1
2

DMAC Hedge Fund Activity: Q4 2020 in Review

36 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2020, worth a combined $60.6M — up 114% from $28.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new DMAC positions and 9 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.4M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $3.21M sold.

  • 36 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2020, up from 33 in Q3 2020.
  • Funds reported $60.6M of DiaMedica Therapeutics stock for Q4 2020, up 114% quarter-over-quarter.
  • 12 funds opened new DiaMedica Therapeutics positions in Q4 2020 and 9 closed out, a net change of +3 holders.
  • The largest DiaMedica Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $2.4M added.
  • The largest DiaMedica Therapeutics seller in Q4 2020 was Nantahala Capital Management, an estimated $3.21M sold.

Based on aggregated 13F filings for Q4 2020.